pubmed-article:9290026 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:9290026 | lifeskim:mentions | umls-concept:C0041296 | lld:lifeskim |
pubmed-article:9290026 | lifeskim:mentions | umls-concept:C0016030 | lld:lifeskim |
pubmed-article:9290026 | lifeskim:mentions | umls-concept:C2709248 | lld:lifeskim |
pubmed-article:9290026 | lifeskim:mentions | umls-concept:C0019409 | lld:lifeskim |
pubmed-article:9290026 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:9290026 | pubmed:dateCreated | 1997-9-5 | lld:pubmed |
pubmed-article:9290026 | pubmed:abstractText | Chronic inflammation and pneumofibrosis are the central events in tuberculosis morphogenesis. It was suggested that a certain type of fibroblasts may play a role in chronization of the inflammation and development of sclerosis in tuberculosis. Fibrous tissue from the foci of secondary tuberculosis (fibrous-cavernous tuberculosis and tuberculomas) of 35 patients were studied light- and electron-microscopically and immunohistochemically. (THY 1-)fibroblasts non-containing lipids and producing insulin-like growth factor 2 (ILGF 2), binding proteins 2 and 4 and epidermal growth factor receptors were found in the foci of secondary tuberculosis close to the granulomatous inflammation and in the new and scarrous fibrous connective tissue of the tuberculoma capsule and caverna walls. These fibroblasts are able for auto- and paracrine regulation of the proliferation of fibroblasts, epithelium and other cells in the inflammatory foci. (THY 1+) fibroblasts containing lipids were observed in the foci of old sclerotic changes among the rough collagen fibres. Thus, (THY 1-) fibroblasts probably play a key role in chronization of inflammation, proliferation and pretumorous dysplasia of pulmonary epithelium in secondary tuberculosis. (THY 1+) fibroblasts containing lipids may show more pronounced collagenesis and may persist under hypoxia condition in the collagenous scars for a long time. | lld:pubmed |
pubmed-article:9290026 | pubmed:language | rus | lld:pubmed |
pubmed-article:9290026 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9290026 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:9290026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:9290026 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:9290026 | pubmed:issn | 0004-1955 | lld:pubmed |
pubmed-article:9290026 | pubmed:author | pubmed-author:SerovV VVV | lld:pubmed |
pubmed-article:9290026 | pubmed:author | pubmed-author:Perel'manM... | lld:pubmed |
pubmed-article:9290026 | pubmed:author | pubmed-author:KoganE AEA | lld:pubmed |
pubmed-article:9290026 | pubmed:author | pubmed-author:SekamovaS MSM | lld:pubmed |
pubmed-article:9290026 | pubmed:author | pubmed-author:Bogadel'nikov... | lld:pubmed |
pubmed-article:9290026 | pubmed:author | pubmed-author:Vitukhnovskai... | lld:pubmed |
pubmed-article:9290026 | pubmed:author | pubmed-author:FippsRR | lld:pubmed |
pubmed-article:9290026 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:9290026 | pubmed:volume | 59 | lld:pubmed |
pubmed-article:9290026 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:9290026 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:9290026 | pubmed:pagination | 49-53 | lld:pubmed |
pubmed-article:9290026 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:meshHeading | pubmed-meshheading:9290026-... | lld:pubmed |
pubmed-article:9290026 | pubmed:articleTitle | [Heterogeneity of pulmonary fibroblasts in tuberculosis]. | lld:pubmed |
pubmed-article:9290026 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:9290026 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:9290026 | pubmed:publicationType | English Abstract | lld:pubmed |
pubmed-article:9290026 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |